重组人脑利钠肽用于重症急性心肌炎伴心力衰竭患者治疗临床研究.docVIP

重组人脑利钠肽用于重症急性心肌炎伴心力衰竭患者治疗临床研究 　　摘 要：目的 研究重组人脑利钠肽应用于重症急性心肌炎伴心力衰竭患者在临床治疗的效果。方法 选取我院2014年1月～2017年6月收治的98例急性心肌炎合并心力衰竭患者，并随机均分为实验组和对照组，每组49例。对照组行常规的抗心力衰竭治疗，实验组在对照组的基础上行静脉泵入重组人脑利钠肽。72 h后测定两组患者用药前后血清N末端脑钠肽前体水平、左室射血分数和Supper-Score的评分。结果 72 h后两组患者N末端脑钠肽前提水平均：用药前对照组实验组，左室射血分数：实验组对照组用药前，差异存在统计学意义（P0.05）。结论 重组人脑利钠肽应用于重症急性心肌炎伴心力衰竭患者的疗效显著，可推广应用。 　　关键词：重组人脑利钠肽；重症急性心肌炎；心力衰竭； 　　中图分类号：R542.21 文献标识码：A DOI：10.3969/j.issn.1006-1959.2018.08.042 　　文章编号：1006-1959（2018）08-0126-03 　　Clinical Study of Recombinant Human Brain Natriuretic Peptide in the Treatment of Patients with Severe Acute Myocarditis and Heart Failure 　　CHENG Lin 　　（Department of Heart，Subject One，Jiamusi Central Hospital，Jiamusi 154002，Heilongjiang，China） 　　Abstract：Objective To study the clinical efficacy of recombinant human brain natriuretic peptide in the treatment of severe acute myocarditis with heart failure.Methods 98 patients with acute myocarditis complicated with heart failure from January 2014 to June 2017 were randomly divided into experimental group and control group with 49 cases in each group.The control group was treated with routine anti-heart failure therapy，on the basis of the control group，the experimental group was injected with recombinant human brain natriuretic peptide.72 h on the basis of the control group.The serum N terminal brain natriuretic peptide level，the left ventricular ejection fraction and the score of Supper-Score were measured before and after the use of the two groups.Results After 72 h，the N terminal brain natriuretic peptide precondition water was mean：before medicationcontrol groupexperimental group，left ventricular ejection fraction：experimental groupcontrol groupbefore medication，the difference was statistically significant（P0.05）.Conclusion Recombinant human brain natriuretic peptide is effective in the treatment of severe acute myocarditis with heart failure，and it can be widely applied. 　　Key words：Recombinant human brain natriuretic peptide；Severe acute myocarditis